News & Updates
Filter by Specialty:
Bimekizumab safety for moderate to severe plaque psoriasis affirmed
Treatment with bimekizumab for up to 2 years appears to be tolerated well in patients with moderate-to-severe plaque psoriasis, with no increased risk of adverse events (AEs) aside from a higher frequency of mild-to-moderate oral candidiasis, according to pooled analyses of data from eight randomized controlled trials (RCTs).
Bimekizumab safety for moderate to severe plaque psoriasis affirmed
20 Sep 2022Can extended duration tinzaparin improve survival in CRC?
Extended duration perioperative thromboprophylaxis with low molecular weight heparin tinzaparin (administered before and for 56 days after surgery) does not lead to longer disease-free survival at 3 years in patients with localized invasive colorectal cancer undergoing surgical resection, reports a study.
Can extended duration tinzaparin improve survival in CRC?
20 Sep 2022Trichomoniasis infection ups prostate cancer, benign prostate hyperplasia risk
Men with Trichomoniasis vaginalis infections appear to be at an elevated risk of prostate cancer (PCa) and benign prostate hyperplasia (BPH), according to a recent study.
Trichomoniasis infection ups prostate cancer, benign prostate hyperplasia risk
20 Sep 2022PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.